Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.

× No keyword cloud information.

16 in total

Review 1. New Strategies and Novel Combinations in EGFR TKI-Resistant Non-small Cell Lung Cancer.

Authors: Nicolas Girard
Journal: Curr Treat Options Oncol Date: 2022-10-15

Review 2. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.

Authors: Alissa J Cooper; Lecia V Sequist; Jessica J Lin
Journal: Nat Rev Clin Oncol Date: 2022-05-09 Impact factor: 65.011

3. Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.

Authors: Toshio Fujino; Kenichi Suda; Takamasa Koga; Akira Hamada; Shuta Ohara; Masato Chiba; Masaki Shimoji; Toshiki Takemoto; Junichi Soh; Tetsuya Mitsudomi
Journal: J Hematol Oncol Date: 2022-06-11 Impact factor: 23.168

Review 4. Emerging strategies to overcome resistance to third-generation EGFR inhibitors.

Authors: Kunyu Shi; Guan Wang; Junping Pei; Jifa Zhang; Jiaxing Wang; Liang Ouyang; Yuxi Wang; Weimin Li
Journal: J Hematol Oncol Date: 2022-07-15 Impact factor: 23.168

5. Blocking both epidermal growth factor receptor and mesenchymal-to-epithelial transition pathways in EGFR-mutated lung cancer.

Authors: Nagio Takigawa; Nobuaki Ochi; Hiromichi Yamane
Journal: Transl Lung Cancer Res Date: 2018-12

Review 6. MET-dependent solid tumours - molecular diagnosis and targeted therapy.

Authors: Robin Guo; Jia Luo; Jason Chang; Natasha Rekhtman; Maria Arcila; Alexander Drilon
Journal: Nat Rev Clin Oncol Date: 2020-06-08 Impact factor: 66.675

7. Increase of secondary mutations may be a drug-resistance mechanism for lung adenocarcinoma after radiation therapy combined with tyrosine kinase inhibitor.

Authors: Hongqing Zhuang; Siyu Shi; Yihang Guo; Zhongqiu Wang
Journal: J Cancer Date: 2019-08-29 Impact factor: 4.207

Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.